RxSight, Inc.

RxSight, Inc. (NASDAQ: RXST) is a commercial-stage medical technology company dedicated to providing customized vision solutions to patients following cataract surgery. The company's proprietary RxSight Light Adjustable Lens system represents the first and only FDA-approved intraocular lens technology that enables physicians to customize and optimize visual acuity for patients after surgery, addressing a significant limitation of conventional premium IOL offerings that cannot be adjusted post-implantation.

The RxSight system comprises three core components: the Light Adjustable Lens, a premium intraocular lens made from proprietary photosensitive silicone material; the Light Delivery Device, an office-based treatment device that delivers ultraviolet light patterns to reshape the lens; and related accessories. The technology leverages photochemistry principles, allowing surgeons to make precise refractive adjustments in 0.25 diopter increments up to three times following surgery, enabling patients to preview and compare possible vision outcomes before selecting their final prescription.

The company began commercial operations in 2019 and maintains a focused presence in the United States, the world's largest premium IOL market. As of December 31, 2025, RxSight had established an installed base of 1,134 Light Delivery Devices in ophthalmology practices, with approximately 300,000 Light Adjustable Lenses implanted since inception. The company's commercial organization includes direct sales personnel, clinical specialists, field service engineers, and marketing staff concentrated on the approximately 3,500 to 4,000 U.S. cataract surgeons performing roughly 60 percent of premium IOL procedures.

RxSight's clinical data demonstrates superior outcomes compared to competing premium IOLs, with 70 percent of patients in FDA trials achieving 20/20 or better uncorrected distance visual acuity without glasses, compared to approximately 40 percent for leading competitor products. The company operates on a "razor and razor blade" business model, generating revenue from both Light Delivery Device sales and ongoing Light Adjustable Lens procedure volumes. The RxSight system has received regulatory approval in the United States, Europe, Canada, Mexico, Singapore, Australia, and South Korea. More information is available at www.rxsight.com.